دورية أكاديمية
Treatment of primary Sjögren's syndrome with D-penicillamine: a pilot study.
| العنوان: | Treatment of primary Sjögren's syndrome with D-penicillamine: a pilot study. |
|---|---|
| المؤلفون: | ter Borg EJ; Department of Rheumatology, Sint Antonius Hospital, Koekoekslaan 1, 3430 EM Nieuwegein, the Netherlands., Haanen HC, Haas FJ, Bistervels JH, Huisman FW, Kerckhaert JA, Kallenberg CG |
| المصدر: | The Netherlands journal of medicine [Neth J Med] 2002 Nov; Vol. 60 (10), pp. 402-6. |
| نوع المنشور: | Comparative Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Van Zuiden Communications Country of Publication: Netherlands NLM ID: 0356133 Publication Model: Print Cited Medium: Print ISSN: 0300-2977 (Print) Linking ISSN: 03002977 NLM ISO Abbreviation: Neth J Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2002- : Alphen aan de Rijn, The Netherlands : Van Zuiden Communications Original Publication: Haarlem, Bohn |
| مواضيع طبية MeSH: | Antirheumatic Agents/*therapeutic use , Penicillamine/*therapeutic use , Sjogren's Syndrome/*drug therapy, Adult ; Aged ; Antirheumatic Agents/adverse effects ; Drug Evaluation ; Female ; Humans ; Male ; Middle Aged ; Netherlands ; Penicillamine/adverse effects ; Pilot Projects ; Sjogren's Syndrome/metabolism |
| مستخلص: | Background: Up to now no satisfying systemic treatment is available for patients with primary Sjögren's syndrome. Methods: In a prospective, open study we investigated the effect of D-penicillamine (first three months 250 mg/day, next three months 500 mg/day) on clinical and immunological parameters in 19 patients with primary Sjögren's syndrome and a mean disease duration of 3.8 years. Results: Eight patients had to stop treatment mainly due to severe (reversible) loss of taste. Clinically, a statistically significant increase in basal salivary flow was observed after three months (p<0.05). In addition, improvement was noted in the Schirmer test and stimulated parotid salivary flow after six months, but these differences were not statistically significant. Laboratory values showed a decrease in ESR (p<0.05) and levels of IgA and IgM (both p<0.02) after six months, a decrease in levels of IgA-Rf and IgM-Rf after three months (both p<0.05), and an increase in haemoglobin level (p<0.05). Conclusion: From this pilot study we conclude that the treatment of primary Sjögren's syndrome with D-penicillamine has only marginal beneficial effects. Together with its clear side effects this means that D-penicillamine is unsuitable for this indication. |
| المشرفين على المادة: | 0 (Antirheumatic Agents) GNN1DV99GX (Penicillamine) |
| تواريخ الأحداث: | Date Created: 20030228 Date Completed: 20030318 Latest Revision: 20131121 |
| رمز التحديث: | 20231215 |
| PMID: | 12607591 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0300-2977 |
|---|